Previously treated patients with advanced NSCLC were enrolled to receive camrelizumab (200 mg, administered intravenously every 3 weeks) and famitinib (20 mg, administered orally once daily). Patients harboring EGFR mutations genes had received at least one EGFR Tyrosine Kinase Inhibitor (TKI) and no more than 2 lines of chemotherapy regimen before the enrollment....For those with EGFR genetic aberrations, the confirmed ORR was 33.3%....Camrelizumab plus famitinib demonstrated encouraging clinical activity with manageable safety profile in previously treated patients with advanced NSCLC.

For those with EGFR genetic aberrations, the confirmed ORR was 33.3%....Camrelizumab plus famitinib demonstrated encouraging clinical activity with manageable safety profile in previously treated patients with advanced NSCLC.